PremiumCompany AnnouncementsBiomX Announces $12M Funding for BX004 Study BiomX announces series of financing for gross proceeds of $12M BiomX regains compliance with NYSE American continued listing standards PremiumCompany AnnouncementsBiomX Shares Phage Therapy Advances and Vision BiomX to present data from Phase 1b/2a study of BX004 BiomX to present cinical trial data for BX004 at ERS PremiumThe FlyBiomX initiated with a Buy at Laidlaw BiomX files to sell 120.15M warrants to buy common stock for holders BiomX appoints Blum to board of directors 
